TESARO

Recent Finacing

Series B

Recent Raise

$101M

TESARO is an oncology-focused biopharmaceutical company developing cancer therapeutics and supportive-care agents, including NK1 antagonist rolapitant for chemotherapy-induced nausea and an in-licensed ALK inhibitor for ALK-positive NSCLC.